Napo pharmaceuticals, a jaguar health family company, sponsoring pediatric gastroenterology conference in abu dhabi and panel discussion about microvillus inclusion disease (mvid)

Jaguar's novel plant-based prescription drug crofelemer has been granted orphan drug designation by the fda and the european medicines agency for both mvid and short bowel syndrome (sbs) with intestinal failure proof-of-concept studies of crofelemer for mvid and sbs planned for 2024 san francisco, ca / accesswire / april 29, 2024 / jaguar health, inc. (nasdaq:jagx) today announced that jaguar family company napo pharmaceuticals (napo) is a bronze sponsor of the 10th annual elite ped-gi congress, which takes place may 2-4, 2024 in abu dhabi in the united arab emirates (uae). additionally, at the conference napo is sponsoring a panel discussion titled "masterclass in congenital diarrhea" which will focus on microvillus inclusion disease (mvid), an ultra-rare congenital diarrheal disorder.
JAGX Ratings Summary
JAGX Quant Ranking